June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
RNA sequencing of sclera from form-deprived guinea pigs identifies multiple signalling pathways underlying myopia
Author Affiliations & Notes
  • Nethrajeith Srinivasalu
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital., Melbourne, VIC, Australia
    School of Psychology, University of Newcastle., Callaghan, NSW, Australia
  • Sally A McFadden
    School of Psychology, University of Newcastle., Callaghan, NSW, Australia
  • Callan Medcalf
    School of Psychology, University of Newcastle., Callaghan, NSW, Australia
  • Gayle Philip
    Victorian Life Sciences Computation Initiative, Melbourne, VIC, Australia
  • Michael Zhang
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital., Melbourne, VIC, Australia
  • Paul N Baird
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital., Melbourne, VIC, Australia
  • Footnotes
    Commercial Relationships Nethrajeith Srinivasalu, None; Sally McFadden, None; Callan Medcalf, None; Gayle Philip, None; Michael Zhang, None; Paul Baird, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5846. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nethrajeith Srinivasalu, Sally A McFadden, Callan Medcalf, Gayle Philip, Michael Zhang, Paul N Baird; RNA sequencing of sclera from form-deprived guinea pigs identifies multiple signalling pathways underlying myopia. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5846.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Remodelling of the posterior sclera accompanies myopia, and in young guinea pig eyes, early changes occur in the peri-papillary zone (PPZ) around the optic nerve. We examined the differential expression of genes in the PPZ sclera to identify significant pathways associated with myopia.

Methods: One eye of guinea pigs (n=3) was form-deprived for 2 weeks (day 6-20) using a translucent diffuser to induce myopia. The other eye was untreated and served as a matched control. At the end of 2 weeks, refractive error was measured in cyclopleged eyes using a Nidek auto-refractor. Posterior scleral punches (4 mm) were collected from the PPZ from myopic and control eyes. Total RNA was extracted using an RNeasy® Fibrous tissue mini kit. RNA was sequenced by a commercial provider using an Illumina HiSeq 2000 platform. RNA-seq data were analysed using three different statistical programs (CuffDiff, edgeR and Voom) and the most differentially expressed genes (p value < 10-3) were used to identify significant pathways.

Results: Form-deprivation induced relative myopia in all animals. The mean difference between myopic and control eyes was -3.76±0.6 D at the end of the treatment period. The number of genes differentially expressed between myopic and control sclera were 26,088, 14,301, and 14,298 using CuffDiff, edgeR and Voom analysis tools, respectively. Differences in gene expression (p<10-3) were found for 850 (CuffDiff), 794 (edgeR) and 270 (Voom) genes using the different analysis programs. Pathway analysis conducted on significant genes identified more than 50 different pathways, of which four have previously been reported as associated with myopia.

Conclusions: Number of differentially expressed genes were identified in the posterior myopic sclera compared to non-myopic eyes, which varied between analysis packages. Several signalling pathways were consistently identified across the different analysis programs with some of these having previously been identified as associated with myopia in humans and animal models. These findings provide insights into potential pathways involved in active scleral remodelling. Further targeted investigation of these genes may provide potential avenues for development of treatment therapies.<br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×